SB 1069 revises Missouri’s restrictions on the sale, purchase, and dispensing of over-the-counter methamphetamine precursor drugs, primarily products containing ephedrine, pseudoephedrine, or phenylpropanolamine. The bill keeps the existing framework that limits sales to the same individual over 24-hour, 30-day, and 12-month periods, but increases the annual purchase/sale cap from 43 grams to 61.2 grams while leaving the 30-day cap at 7.2 grams and the 24-hour cap at 3.6 grams. It also continues to require these products to be sold from behind a pharmacy counter, tracked through pharmacy reporting systems, and subject to law-enforcement inspection of logs and records.
The bill adds a new manufacturer fee structure tied to the real-time electronic pseudoephedrine tracking system, beginning October 1, 2026. Manufacturers of covered products sold in or into Missouri would have to pay monthly fees set by the system administrator and provide proof of payment upon request by the Department of Health and Senior Services. The bill also preserves the rule that no prescription is required for sales within the statutory limits, while maintaining special provisions for local preemption and for certain animal feed or naturally occurring ephedra products.
SB 1069 would amend sections 195.417 and 579.060, RSMo, and would expand the criminal provisions governing unlawful sale, distribution, or purchase of methamphetamine precursor drugs. Violations remain a class A misdemeanor, and the bill updates the offense language to reflect the revised annual gram limit, pharmacy-counter requirements, electronic logging duties, and the new manufacturer fee obligation. It also retains the existing mechanism that can trigger expiration of the no-prescription rule if methamphetamine laboratory seizures exceed a statewide threshold.
The general sentiment reflected by the bill text is regulatory and enforcement-oriented, with the apparent goal of balancing access to cold medicines against methamphetamine diversion concerns. Because there are no committee transcripts or votes provided, there is no recorded debate or formal vote history to indicate broader support or opposition. Based on the structure of the bill, the main policy emphasis appears to be tightening oversight and funding the tracking system rather than loosening controls.
The most likely points of contention are the increased annual purchase limit, the new fees imposed on manufacturers, and the continued state preemption of local ordinances. Retail pharmacies and manufacturers may be affected by the reporting, counter-placement, and fee requirements, while law enforcement and public health officials would likely support the tracking and enforcement provisions. Local governments that previously adopted stricter prescription requirements would be limited by the bill’s preemption language.
SB 1069 would amend Missouri’s controlled-substances and pharmacy-related statutes, specifically sections 195.417 and 579.060, to change the legal limits and enforcement rules for pseudoephedrine- and ephedrine-containing products. It raises the annual quantity threshold from 43 grams to 61.2 grams, keeps the 30-day and 24-hour limits in place, adds manufacturer fee obligations for the pseudoephedrine tracking system, and continues to impose misdemeanor penalties for knowing violations. The bill also preserves state preemption over local ordinances regulating these products and maintains pharmacy-counter, reporting, and electronic log requirements for covered sales.
The bill appears to have a generally cautious, enforcement-focused tone, aimed at preventing methamphetamine production while preserving over-the-counter access within set limits. With no committee discussion or vote record available, there is no direct evidence of partisan or stakeholder sentiment in the provided materials. The text itself suggests an attempt to balance public access to decongestants with stronger monitoring and funding for diversion controls.
Likely points of contention include the increase in the annual purchase limit, which could be viewed as making precursor drugs more accessible, and the new monthly fees on manufacturers, which shift compliance costs to industry. The bill’s preemption of local ordinances may also be controversial for municipalities that want stricter controls than state law allows. Pharmacies may be concerned about reporting and counter-placement obligations, while law enforcement and anti-methamphetamine advocates are likely to support the tracking and penalty provisions.